Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
71.75
+0.37 (0.52%)
At close: Sep 1, 2026, 4:00 PM EDT
72.20
+0.45 (0.63%)
After-hours: Sep 1, 2026, 4:31 PM EDT
Nektar Therapeutics Employees
Nektar Therapeutics had 63 employees as of December 31, 2025. The number of employees increased by 2 or 3.28% compared to the previous year.
Employees
63
Change (1Y)
2
Growth (1Y)
3.28%
Revenue / Employee
$866,492
Profits / Employee
-$2,494,079
Market Cap
2.45B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 63 | 2 | 3.28% |
| Dec 31, 2024 | 61 | -76 | -55.47% |
| Dec 31, 2023 | 137 | -79 | -36.57% |
| Dec 31, 2022 | 216 | -524 | -70.81% |
| Dec 31, 2021 | 740 | 22 | 3.06% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Vera Therapeutics | 361 |
| Nuvation Bio | 305 |
| Biohaven | 274 |
| Viridian Therapeutics | 252 |
| Precigen | 160 |
| Pharvaris | 148 |
| Kodiak Sciences | 141 |
NKTR News
- 4 days ago - Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 7 days ago - Nektar’s rezpegaldesleukin featured in published atopic dermatitis trial - TheFly
- 7 days ago - Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis - PRNewsWire
- 11 days ago - Nektar reinstated with a Neutral at JPMorgan - TheFly
- 16 days ago - Nektar reports Q2 EPS ($1.23), consensus ($2.04) - TheFly
- 19 days ago - Nektar Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 19 days ago - Nektar Therapeutics Earnings release: Q2 2026 - Filings
- 19 days ago - Nektar Therapeutics Quarterly report: Q2 2026 - Filings